Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery

JAMA Ophthalmology

Volumn 135, Issue 4, 2017, Pages 363-368

  Eadie, Brennan D ^a   Etminan, Mahyar ^a   Carleton, Bruce C ^a,b,c   Maberley, David A ^a   Mikelberg, Frederick S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BRITISH COLUMBIA; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURGICAL RISK; TRABECULECTOMY; VERY ELDERLY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY; PROSTHESIS IMPLANTATION; RETREATMENT; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRITISH COLUMBIA; CASE-CONTROL STUDIES; FEMALE; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANTS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; PHARMACOEPIDEMIOLOGY; PROSTHESIS IMPLANTATION; RETREATMENT; RISK FACTORS; TRABECULECTOMY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 85017657935     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2017.0059     Document Type: Article

References (38)

1. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1432-1444.
3. Heier JS, Brown DM, Chong V, et al.; VIEW1 and VIEW2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2013; 120(1): 209-210.
4. Nguyen QD, Shah SM, Heier JS, et al.; READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology. 2009; 116(11): 2175-2181.e1.
5. Nguyen QD, Brown DM, Marcus DM, et al.; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4): 789-801.
6. Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13): 1193-1203.
7. Campochiaro PA, Heier JS, Feiner L, et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6): 1102-1112.e1.
8. Brown DM, Campochiaro PA, Singh RP, et al.; CRUISE Investigators. Ranibizumab for macula edema following central retinal vein occlusion: six-month primary end point results in a phase III study. Ophthalmology. 2010; 117(6): 1124-1133.
9. Clark WL, Boyer DS, Heier JS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. Ophthalmology. 2016; 123(2): 330-336.
10. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase3 COPERNICUS study. Ophthalmology. 2012; 119(5): 1024-1032.
11. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-583.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1): 43-58.e1.
13. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond). 2007; 21 (12): 1541.
14. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246(7): 955-958.
15. Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009; 40(3): 293-295.
16. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010; 26(1): 105-110.
17. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011; 95(8): 1111-1114.
18. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011; 31(6): 1028-1035.
19. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013; 33 (1): 179-187.
20. Bressler SB, Almukhtar T, Bhorade A, et al.; Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol. 2015; 133(5): 589-597.
21. Baek SU, Park IW, Suh W. Long-term intraocular pressure changes after intravitreal injection of bevacizumab. Cutan Ocul Toxicol. 2016; 35(4): 310-314.
22. Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012; 43(4): 328-334.
23. Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012; 307(13): 1414-1419.
24. Zhang T, Smith MA, Camp PG, Shajari S, MacLeod SM, Carleton BC. Prescription drug dispensing profiles for one million children: a population-based analysis. Eur J Clin Pharmacol. 2013; 69(3): 581-588.
25. Etminan M, Maberley DA, Babiuk DW, Carleton BC. Risk of myocardial infarction and stroke with single or repeated doses of intravitreal bevacizumab in age-related macular degeneration. Am J Ophthalmol. 2016; 163: 53-58.
26. British Columbia Ministry of Health. Discharge Abstract Database (Hospital Separations file). British Columbia Ministry of Health. https://www.popdata.bc.ca/data/internal/health/dad. Accessed February 23, 2016.
27. British Columbia Ministry of Health. Medical Services Plan (MSP) Payment Information File. British Columbia Ministry of Health. https://www.popdata.bc.ca/data/internal/health/msp. Accessed February 23, 2016.
28. British Columbia Ministry of Health. PharmaNet. British Columbia Ministry of Health http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/pharmanet-bc-s-drug-information-network. Accessed February 23, 2016.
29. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191-2194. doi: 10.1001/jama.2013.281053
30. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012; 35(12): 2665-2673.
31. Langholz B, Clayton D. Sampling strategies in nested case-control studies. Environ Health Perspect. 1994; 102(Suppl. 8): 47-51.
32. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009; 20 (4): 488-495.
33. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB. Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2014; 158(2): 319-327.e2.
34. Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther. 2015; 31(1): 2-10.
35. SooHoo JR, Seibold LK, Kahook MY. The link between intravitreal antivascular endothelial growth factor injections and glaucoma. Curr Opin Ophthalmol. 2014; 25(2): 127-133.
36. Bakri SJ, Moshfeghi DM, Rundle A, et al. Eyes treated with monthly ranibizumab: a post hoc analysis ofdata from the MARINA and ANCHOR trials. Paper presented at: AAO Annual Meeting; October 15, 2010; Chicago, IL.
37. Yannuzzi NA, Klufas MA, Quach L, et al. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015; 133(1): 32-39.
38. Fielden M, Nelson B, Kherani A. Acute intraocular inflammation following intravitreal injection of bevacizumab - a large cluster of cases. Acta Ophthalmol. 2011; 89(8): e664-e665.